Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspects.

David C Fry1, Bradford Graves, Lyubomir T Vassilev

  • 1Structural Chemistry Group, Hoffmann-La Roche, Inc., Nutley, New Jersey, USA.

Methods in Enzymology
|December 13, 2005
PubMed
Summary

Researchers developed small-molecule inhibitors targeting the MDM2 E3 ligase and p53 interaction. Structural information was crucial for designing these potent inhibitors, offering a new strategy for modulating protein-protein interactions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Extent and Nature of Lived Experience Engagement in the Development of Australian Clinical Practice Guidelines, 2014-2025: A Scoping Review.

The Medical journal of Australia·2026
Same author

Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations.

The Medical journal of Australia·2025
Same author

Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development.

ACS medicinal chemistry letters·2025
Same author

Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development.

Journal of medicinal chemistry·2023
Same author

Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.

Molecular cancer therapeutics·2023
Same author

FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.

Targeted oncology·2023

Area of Science:

  • Biochemistry
  • Structural Biology
  • Drug Discovery

Background:

  • Inhibiting E3 ligase-substrate binding is key to blocking protein ubiquitylation and degradation.
  • Protein-protein interactions are challenging targets for selective small-molecule drug discovery.
  • The interaction between MDM2 E3 ligase and its substrate p53 is a critical pathway.

Purpose of the Study:

  • To develop the first potent and selective small-molecule inhibitors targeting the MDM2-p53 interaction.
  • To demonstrate the utility of structural information in drug discovery for protein-protein interactions.
  • To provide a framework for developing inhibitors of similar protein-protein interactions.

Main Methods:

  • Utilized structural information to guide inhibitor design.

Related Experiment Videos

  • Employed high-throughput screening to identify initial hits.
  • Applied structure-based drug design principles for lead optimization.
  • Analyzed inhibitor binding strategies.

    • Main Results:

    • Successfully developed potent and selective small-molecule inhibitors of MDM2-p53 binding.
    • Demonstrated the critical role of structural data in assessing targets and optimizing leads.
    • Established a methodology applicable to other protein-protein interaction targets.

    Conclusions:

    • Structural information is invaluable for developing small-molecule inhibitors of E3 ligase-substrate interactions.
    • The developed inhibitors represent a significant advancement in targeting protein-protein interactions for therapeutic purposes.
    • This approach provides a versatile platform for future drug discovery efforts targeting protein-protein interactions.